SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma

PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.

Subsidie
€ 1.999.401
2023

Projectdetails

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with few treatment options. Recently, the chemical space for targeted therapeutics was significantly increased by the development of compounds that induce protein degradation (PROTACs), but so far, they are unavailable for PDAC. The main motivation of PROTAC-PDAC is to develop novel targeted therapies for PDAC.

Project Background

The project is based on our accomplishments in three crucial areas:

  1. My group identified – as target candidates – a series of transcription factors that are absolutely required for PDAC growth in vivo.
  2. We developed dozens of potent, specific PROTACs, thereby gaining deep insight into the underlying design principles and synthesis procedures.
  3. We established genetic models in mice for simulating PROTAC function and discovering ideal target–E3 ligase pairs.

Project Aims

In PROTAC-PDAC, we will develop compounds that degrade key oncogenic transcription factors and inhibit pancreatic tumor growth with minimal toxicity in healthy tissues.

Aim I

We will start by implementing the Auxin degron system in a murine PDAC model to induce degradation of the target candidates and select four priority targets with the highest therapeutic index.

Aim II

Then, we will assess their oncogenic functions by analyzing molecular, cellular, and organismic consequences of acute depletion in mice.

Aim III

In parallel, we will develop pharmaceutical PROTACs to induce target degradation and analyze their efficacy in PDAC models.

Aim IV

Finally, with the aim of developing less toxic PDAC therapy, we will identify pancreatic E3 ligases for the design of the first tissue-specific PROTACs that induce target degradation primarily in pancreatic tumor cells.

Conclusion

While the main goal of PROTAC-PDAC is to develop new PROTAC-based therapeutic strategies, we will also establish groundbreaking methods and models leading to fundamental discoveries in PDAC biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.401
Totale projectbegroting€ 1.999.401

Tijdlijn

Startdatum1-12-2023
Einddatum30-11-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIELpenvoerder
  • JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG

Land(en)

Germany

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.

ERC Starting...€ 1.499.625
2022
Details

Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy

This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.

ERC Proof of...€ 150.000
2022
Details

Actionable metabolite supplements to improve treatment response in pancreatic cancer

The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.

ERC Proof of...€ 150.000
2024
Details

KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS

The project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company.

ERC Proof of...€ 150.000
2023
Details

Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy

PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.

ERC Consolid...€ 1.842.642
2022
Details
ERC Starting...

Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.

ERC Starting Grant
€ 1.499.625
2022
Details
ERC Proof of...

Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy

This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.

ERC Proof of Concept
€ 150.000
2022
Details
ERC Proof of...

Actionable metabolite supplements to improve treatment response in pancreatic cancer

The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Proof of...

KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS

The project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company.

ERC Proof of Concept
€ 150.000
2023
Details
ERC Consolid...

Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy

PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.

ERC Consolidator Grant
€ 1.842.642
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.

EIC Accelerator€ 2.494.504
2023
Details

PRO CellecT

Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.

Mkb-innovati...€ 20.000
2021
Details

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

Mkb-innovati...€ 20.000
2020
Details

Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.

EIC Pathfinder€ 2.988.461
2024
Details

A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.

APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes.

EIC Pathfinder€ 2.321.677
2022
Details
EIC Accelerator

FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.

EIC Accelerator
€ 2.494.504
2023
Details
Mkb-innovati...

PRO CellecT

Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2021
Details
Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2020
Details
EIC Pathfinder

Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.

EIC Pathfinder
€ 2.988.461
2024
Details
EIC Pathfinder

A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.

APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes.

EIC Pathfinder
€ 2.321.677
2022
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.